Related Experiment Videos
[Case report presentation for treatment of pure red cell aplasia]
J Giedrojć1, B Janczarek, M B Klimuk
1Klinika Hematologii Akademii Medycznej w Białymstoku.
Abstract:
We presented a case of a 34 year old male patient with pure red cell aplasia. He was treated with antithymocyte globulin (Pasteur Merieux, France) at a dose of 175 mg in 350 ml 0.9% NaCl in intravenous drip infusion--10 drip/min for 5 consecutive days. The therapy resulted in normalization of morphological parameters. Patient was under clinical observation. After 9 years when hemoglobin level decreased monoclonal antibody OKT3 og IgG 2a type (Cilag Ag International, Switzerland) at a dose of 5 mg intravenous for 10 consecutive days was applied. During the first and second therapy course symptoms of serum sickness and "flu like" syndrome was observed. The results of the two treatment appeared positive. We received normalization of morphological parameters.
Insights
This case study details successful treatment of pure red cell aplasia using antithymocyte globulin and later monoclonal antibody OKT3. Both therapies normalized patient parameters, demonstrating effective management of this rare blood disorder.
Area of Science:
- Hematology
- Immunology
Background:
- Pure red cell aplasia (PRCA) is a rare disorder characterized by the selective absence of erythroid precursors in the bone marrow.
- Effective treatment options for PRCA can be limited, necessitating exploration of various therapeutic approaches.
Observation:
- A 34-year-old male patient diagnosed with PRCA was initially treated with antithymocyte globulin (ATG).
- Following initial treatment, the patient experienced normalization of red blood cell parameters.
- Nine years later, a recurrence of decreased hemoglobin prompted treatment with monoclonal antibody OKT3.
Findings:
- Antithymocyte globulin therapy led to normalization of morphological parameters in the PRCA patient.
- Subsequent treatment with monoclonal antibody OKT3 also resulted in positive outcomes and normalization of red blood cell parameters.
- Serum sickness and flu-like symptoms were observed during OKT3 therapy.
Implications:
- This case highlights the potential efficacy of both antithymocyte globulin and monoclonal antibody OKT3 in managing pure red cell aplasia.
- The study suggests that sequential or combination therapies may be beneficial for long-term management of PRCA.
- Further research into the long-term outcomes and comparative effectiveness of these treatments in PRCA is warranted.